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Abstract: Purpose:  To evaluate the effect of a new nutritional supplement based on melatonin
on the intraocular pressure (IOP) in normotensive subjects.
Patients and Methods:  A short-term and prospective study was designed. Sixty-seven
normotensive subjects were recruited. Patients were divided in two groups. The daily
group (DG) (n=18) were instructed to take the supplement from 22.00 to 23.00 (before
sleeping) during 3 consecutive days. IOP was measured from 10.00 to 11.00 am the
day before treatment and during the 3 days of experiment. The acute group (AG)
(n=49) was instructed to take the supplement after the second measure (11.00) of the
second day. IOP was measured 1 hour and just before the intake of the supplement
and one and two hours after. All measures in this group were taken one day before
without any supplement (control) and the day of experiment.
Results:  The DG group showed a significant decreasing in IOP after supplement
intake in all days of experiment, from 14.9±3.4 mmHg to 13.8±2.9 mmHg after 3 days
of experiment (p value<0.001). For AG, IOP did not change during the control day,
however, a reduction of 1 mmHg was found two and three hours after supplement
intake, from 15.7±2.5 mmHg to 14.7±2.5 mmHg and 15.1±2.7 mmHg, respectively,
being statistically significant (p value<0.001).
Conclusion:  The supplement based on melatonin was able to reduce the IOP in
normotensives subjects after 2 hours of intake. Moreover, the daily intake showed a
reduction of IOP during the three days of experiment.
Response to Reviewers: Reviewer #1: The work is an interesting one, which offers another target for the
treatment of ocular hypertension and glaucoma, but the methodology is quite
worrisome.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
The findings from this study would have been objective, if the study were properly
designed.
The study design would have been a controlled randomised clinical trial, to elucidate
the objective effect of melatonin on IOP.
The purpose of this study was to corroborate the effect of melatonin on IOP of
normotensive patients that was achieve many years ago by Samples (Effect of
melatonin on intraocular pressure, Samples JR, Krause G, Lewy AJ. Curr Eye Res.
1988 Jul;7(7):649-53), and to probe that melatonin not only decrease IOP in an acute
way, but also that this effect could be detected after the acute effect finished.
Although there is no placebo group in this study, there is a basal IOP from all patients
at the same time points studied, that has a better correlation with the final IOP than
comparing two different groups.
It would have been age and sex-matched, with equal number of participants in each
arm, who were not statistically different.
While there is a difference between male and female patients (1.8:1 ratio), there is no
correlation between gender and IOP excluding pregnancy and breastfeeding (Gender
difference in the pathophysiology and treatment of glaucoma. Tehrani S Curr Eye Res.
2015 Feb;40(2):191-200) and there is no report about this possibility in melatonin’s
effect.
There should have been a control group, who were given placebo.
Although there is no placebo group in this study, there is a basal IOP from all patients
at the same time points studied, that has a better correlation with the final IOP than
comparing two different groups. That is why we decided to make crossed study better
than a parallel one with placebo group.
Considering the diurnal / nocturnal variations in IOP, the exact time of ingestion of the
supplement for both groups should have been specified.
All patients from AG received the supplement from 10:00 to 11:00 with measures the
day before and the same day.
Patients from DG received the supplement at 22:00 the 3 days.
Both sentences has been added to the text in abstract and at line 68, in order to clarify
that.
IOP values from the placebo group would have ruled out the diurnal / nocturnal
variations and highlighted the significance of the values in DG and AG.
We know that there is a variation in IOP during all day, and that is why we have
decided to take the intraocular pressure at the same time during both days (the control
one and the treated one). With these two days, we are able to compare which is the
normal diurnal variation and which is made by melatonin supplement.
On the DG, there is also measures from the first day without any treatment, which can
be also considered as basal values. In order to compare the results, the two first
measures of the first day (10:00 and 11:00) were used as basal values and the same
measures were made on the others to avoid day variations.
Why was it only one-time ingestion by AG and not for 3 mornings?
Because the main outcome of this group was to assess its acute effect which last from
2 to 4 hours, not the daily effect.
Taking into account that the same patients could not be used for both experiments, we
decided to split them and check separately the acute effect and the daily or chronic
treatment.
Why were the participants not examined to confirm the absence of normal pressure
glaucoma?
Patients were examined and consulted about this point on its anamnesis to ensure
there were no ophthalmic diseases like glaucoma or any retinal one. We have included
in the text at line 54.
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ABSTRACT 1 
Purpose: To evaluate the effect of a new nutritional supplement based on melatonin 2 
on the intraocular pressure (IOP) in normotensive subjects. 3 
Patients and Methods: A short-term and prospective study was designed. Sixty-seven 4 
normotensive subjects were recruited. Patients were divided in two groups. The daily 5 
group (DG) (n=18) were instructed to take the supplement at night from 22.00 to 23.00 6 
(before sleeping) during 3 consecutive days. IOP was measured at from 10.00 to 11.00 7 
am the day before treatment and during the 3 days of experiment. The acute group 8 
(AG) (n=49) was instructed to take the supplement after the second measure (11.00) of 9 
the second dayin the morning only one day. IOP was measured 1 hour and just before 10 
the intake of the supplement and one and two hours after. All measures in this group 11 
were taken one day after before without any supplement (control) and the day of 12 
experiment. 13 
 Results: The DG group showed a significant decreasing in IOP after supplement 14 
intake in all days of experiment, from 14.9±3.4 mmHg to 13.8±2.9 mmHg after 3 days 15 
of experiment (p value<0.001). For AG, IOP did not change during the control day, 16 
however, a reduction of 1 mmHg was found two and three hours after supplement 17 
intake, from 15.7±2.5 mmHg to 14.7±2.5 mmHg and 15.1±2.7 mmHg, respectively, 18 
being statistically significant (p value<0.001). 19 
Conclusion: The supplement based on melatonin was able to reduce the IOP in 20 
normotensives subjects after 2 hours of intake. Moreover, the daily intake showed a 21 
reduction of IOP during all the three days of experiment. 22 
Keywords:   Melatonin; supplements; Intraocular pressure; coadjuvant treatments23 
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Ocular hypertension is an anomalous physiological situation related to the appearance 24 
of ocular pathologies such as glaucoma. The relationship between ocular hypertension 25 
and glaucomatous pathology has been well known for many years. Even today, ocular 26 
hypertension is still considered the most important risk factor for the development of 27 
this disease [1].  28 
 29 
Melatonin is an neurohormone that not only is produced by the pineal gland but is also 30 
synthesized and released by some ocular structures such as the retina, ciliary body or 31 
the lens [2]. Osborne described that melatonin is involved in the control of the aqueous 32 
humour dynamics[3]. In this sense, studies performed in animal models suggested that 33 
melatonin and its analogues can reduce IOP in normotensive and hypertensive 34 
eyes[4]. This control of IOP carried out by melatonin has invited to use of this 35 
compound and its analogues for the treatment of ocular hypertension and glaucoma[5]. 36 
There are some studies in humans that show the similar effect after melatonin intake 37 
[6-8]. 38 
 39 
A new nutritional supplement as coadjuvant treatment has been developed, based on 40 
melatonin to reduce the IOP and other components to improve the other three 41 
fundamental concerns of glaucomatous pathology: the elimination of free radicals, the 42 
protection and reinforcement of the nervous system and the increase in retinal blood 43 
supply [9, 10]. The objective of this study was to evaluate the possible acute and daily 44 
effect of a new nutritional supplement based on melatonin on the intraocular pressure 45 
(IOP) in normotensive subjects. 46 
 47 
A short-term, prospective and randomized study has been performed. Sixty-seven 48 
normotensives subjects were recruited from the Optometry Clinic of the Faculty of 49 
Optics and optometry (University Complutense of Madrid, Spain).  Mean age was 50 
42.64 ± 9.01 years (range 23 to 54 years), being 43 men and 24 women. Before 51 
beginning the study, the risks and benefits of the treatment were explained, and 52 
informed consent was obtained from all subjects. Once included, each subject was 53 
examined by ophthalmologist in order to detect any eye disease not mentioned before. 54 
Participants were free to leave the study at any time. The study was conducted in 55 
compliance with good clinical practice guidelines, institutional review board regulations 56 
(IRB number approval: 18.444 O-P) and the tenets of the Declaration of Helsinki 57 
revised in 2013 [11].  58 
 59 
A specific nutritional supplement for glaucoma was evaluated (Visaid Press; Avizor SA; 60 
Madrid, Spain). This supplement is based on melatonin (1 mg), due its antioxidant and 61 
hypotensor efficacy [10], and accompanied by vitamin B6 for its properties acting on 62 
the nervous system [12], anthocyanins, as blood flow promoter [13], Docosahexaenoic 63 
acid (DHA), Eicosapentaenoic acid (EPA) and manganese. The supplements are 64 
administered as a gel pill. The manufacturer intake recommendation is one pill at night. 65 
 66 
Subjects were randomly divided in two groups. The daily group (DG) (n=18) were 67 
instructed to take the supplement from 22.00 to 23.00, before going to sleep, during 3 68 
consecutive days. IOP was measured at 10.00 and 11.00 am one day before, as 69 
baseline, and during the 3 days of experiment at the same time points. The acute 70 
group (AG) (n=49) was instructed to take the supplement at the morning only during 71 
one day. IOP was measured 1 hour and just before to take the supplement and one 72 
and two hours after. All measures in this group were taken one day after before without 73 
any supplement (control) and the day of experiment by the same experienced 74 
examiners (C.R and J.B.).  75 
 76 
For IOP measurement, VX-130 platform (Luneau, Technologies, Chartres, France) was 77 
used. The VX130 is a multi-diagnostic platform that combines non-contact tonometer 78 
(air puff based) with Hartmann–Shack based autorefraction and Placido-disk and 79 
Scheimpflug based corneal-topography. Three measurements were taken on each 80 
subject and the average of the readings was recorded as the final IOP. The mean of 81 
measures at 10.00 and 11.00 was considered as basal value for each day. During the 82 
measurement, subjects were asked to keep the eye open and fixate to the light 83 
stimulus of the device.  84 
 85 
Data were analysed by statistical package SPSS version 22.0 for Windows (SPSS, 86 
Inc., Chicago, IL). The values presented are the means ± SD of the experiments 87 
performed. Parametric tests were used to compare the studied groups. Differences 88 
between baseline and after supplement intake in both groups were estimated by the 89 
Student - t test for related samples. One-way ANOVA for related samples were used to 90 
evaluate the trend of IOP in DG group. P <0.05 was considered statistically significant. 91 
 92 
The DG group showed a significant decreasing in IOP after supplement intake in all 93 
days of experiment compared with baseline, being 14.9 ± 3.4 mmHg for baseline and 94 
14.1 ± 2.7 mmHg, 13.6 ± 2.7 mmHg and 13.8 ± 2.9 mmHg after 24 hours, 48 hours and 95 
72 hours of experiment, respectively (p value<0.001; Student t-test for related 96 
samples). Moreover, the IOP trend during the complete experiment was to decrease, 97 
being statistically significant (p value<0.05; One-way ANOVA for related) Figure 1. 98 
 99 
Regarding AG group, IOP did not change during the control day, being 15.7 ± 2.4 100 
mmHg before to supplement intake and 15.6 ± 2.5 mmHg and 15.6 ± 2.6 mmHg after 101 
two and three hours, respectively (p value > 0.05; Student t-test for related samples). 102 
However, a reduction of 1 mmHg was found 2 hours after supplement intake, from 103 
15.7±2.5 mmHg to 14.7±2.5 mmHg, being statistically significant (p value < 0.05; 104 
Student t-test for related samples). After three hours, IOP followed being statistically 105 
inferior than baseline, with a mean value of 15.1±2.7 mmHg (p value < 0.05; Student t-106 
test for related samples). Figure 2. 107 
 108 
The nutritional supplement based on melatonin decreased IOP in normotensive 109 
subjects in both experiments performed. A single dose reduces IOP around 7% after 110 
two hours of its ingest and the consecutive intake for three days was able to reduce it 111 
around 9%.  112 
 113 
The effect of melatonin or analogues over IOP has been previously described in 114 
humans by oral intake. Samples et al. found that oral melatonin administration (500 115 
mg) reduced IOP in normal subject around 10% [8]. Pescosolido et al. found that 116 
agomelatine, a melatonin analogue, was able to reduce IOP around 30% after oral 117 
treatment in a group of primary open angle glaucoma patients. These patients were 118 
treated with 25 mg of agomelatine for psychiatric conditions [6]. Another study, 119 
published in 2009, has demonstrated IOP reduction when patients that underwent 120 
cataract surgery were treated with melatonin. These patients were treated with 10 mg 121 
of melatonin and IOP decreased significantly from 17.9 ± 0.9 to 14.2 ± 1.0 mmHg after 122 
premedication and to 13.8 ± 1.1 mmHg during surgery [7].  Both studies found an IOP 123 
reduction higher that the present trial probably due to the different concentration 124 
ingested and to the initial patient IOP.   125 
 126 
The main limitation of the study is that there is no placebo group, but results are 127 
compared to the measures of the same patient at the same time points in the previous 128 
day. It should also be considered that the use measures are performed ofwith non-129 
contact tonometer based on air-puff.  Some studies found that the non-contact 130 
tonometry gives higher results than Goldman tonometry, especially in adult subjects 131 
and hypertensive patients [14]. But, the repeatability of non-contact tonometry has 132 
been previously described in normotensive population [15].  It is should be important to 133 
perform the same study with a placebo group and Goldman or Perkins tonometry in 134 
both normotensives and hypertensive patients to corroborate the outcomes of this 135 
study. 136 
 137 
The nutritional supplement evaluated is composed for other components with 138 
interesting features for glaucoma as it has been mentioned in methods section and, 139 
taking account the outcomes found in the current study, it would be interesting to 140 
design and develop some long-term studies to evaluate the supplement effect in retina 141 
protection. 142 
 143 
In conclusion, the nutritional supplement based on melatonin seems to decrease the 144 
IOP in normotensive subjects. These outcomes indicate that melatonin 145 
supplementation could be a coadjuvant treatment of glaucoma. Nevertheless, it is 146 
mandatory to confirm this role in glaucomatous patients compared with placebo group 147 
and with more studies about IOP changes after supplement intake. 148 
 149 
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FIGURES LEGENDS 210 
 211 
FIGURE 1. Effect on IOP during the three days of experiment in daily group (DG). 212 
n=18. It is represented the mean and standard error of the mean (SEM). * p 213 
value<0.05; after intake vs before intake (PRE) (Student t-test for related samples). 214 
 215 
 216 
FIGURE 2. Effect on IOP after two and three hours of a unique melatonin supplement 217 
intake in acute group (AG). n=49. It is represented the mean and standard error of the 218 
mean (SEM). * p value<0.05; after intake vs before intake (PRE) (Student t-test for 219 
related samples). 220 
 221 
ABSTRACT 1 
Purpose: To evaluate the effect of a new nutritional supplement based on melatonin 2 
on the intraocular pressure (IOP) in normotensive subjects. 3 
Patients and Methods: A short-term and prospective study was designed. Sixty-seven 4 
normotensive subjects were recruited. Patients were divided in two groups. The daily 5 
group (DG) (n=18) were instructed to take the supplement from 22.00 to 23.00 (before 6 
sleeping) during 3 consecutive days. IOP was measured from 10.00 to 11.00 am the 7 
day before treatment and during the 3 days of experiment. The acute group (AG) 8 
(n=49) was instructed to take the supplement after the second measure (11.00) of the 9 
second day. IOP was measured 1 hour and just before the intake of the supplement 10 
and one and two hours after. All measures in this group were taken one day before 11 
without any supplement (control) and the day of experiment. 12 
Results: The DG group showed a significant decreasing in IOP after supplement 13 
intake in all days of experiment, from 14.9±3.4 mmHg to 13.8±2.9 mmHg after 3 days 14 
of experiment (p value<0.001). For AG, IOP did not change during the control day, 15 
however, a reduction of 1 mmHg was found two and three hours after supplement 16 
intake, from 15.7±2.5 mmHg to 14.7±2.5 mmHg and 15.1±2.7 mmHg, respectively, 17 
being statistically significant (p value<0.001). 18 
Conclusion: The supplement based on melatonin was able to reduce the IOP in 19 
normotensives subjects after 2 hours of intake. Moreover, the daily intake showed a 20 
reduction of IOP during the three days of experiment. 21 
Keywords:   Melatonin; supplements; Intraocular pressure; coadjuvant treatments22 
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Ocular hypertension is an anomalous physiological situation related to the appearance 23 
of ocular pathologies such as glaucoma. The relationship between ocular hypertension 24 
and glaucomatous pathology has been well known for many years. Even today, ocular 25 
hypertension is still considered the most important risk factor for the development of 26 
this disease [1].  27 
 28 
Melatonin is an neurohormone that not only is produced by the pineal gland but is also 29 
synthesized and released by some ocular structures such as the retina, ciliary body or 30 
the lens [2]. Osborne described that melatonin is involved in the control of the aqueous 31 
humour dynamics[3]. In this sense, studies performed in animal models suggested that 32 
melatonin and its analogues can reduce IOP in normotensive and hypertensive 33 
eyes[4]. This control of IOP carried out by melatonin has invited to use of this 34 
compound and its analogues for the treatment of ocular hypertension and glaucoma[5]. 35 
There are some studies in humans that show the similar effect after melatonin intake 36 
[6-8]. 37 
 38 
A new nutritional supplement as coadjuvant treatment has been developed, based on 39 
melatonin to reduce the IOP and other components to improve the other three 40 
fundamental concerns of glaucomatous pathology: the elimination of free radicals, the 41 
protection and reinforcement of the nervous system and the increase in retinal blood 42 
supply [9, 10]. The objective of this study was to evaluate the possible acute and daily 43 
effect of a new nutritional supplement based on melatonin on the intraocular pressure 44 
(IOP) in normotensive subjects. 45 
 46 
A short-term, prospective and randomized study has been performed. Sixty-seven 47 
normotensives subjects were recruited from the Optometry Clinic of the Faculty of 48 
Optics and optometry (University Complutense of Madrid, Spain). Mean age was 42.64 49 
± 9.01 years (range 23 to 54 years), being 43 men and 24 women. Before beginning 50 
the study, the risks and benefits of the treatment were explained, and informed consent 51 
was obtained from all subjects. Once included, each subject was examined by 52 
ophthalmologist in order to detect any eye disease not mentioned before. Participants 53 
were free to leave the study at any time. The study was conducted in compliance with 54 
good clinical practice guidelines, institutional review board regulations (IRB number 55 
approval: 18.444 O-P) and the tenets of the Declaration of Helsinki revised in 2013 56 
[11].  57 
 58 
A specific nutritional supplement for glaucoma was evaluated (Visaid Press; Avizor SA; 59 
Madrid, Spain). This supplement is based on melatonin (1 mg), due its antioxidant and 60 
hypotensor efficacy [10], and accompanied by vitamin B6 for its properties acting on 61 
the nervous system [12], anthocyanins, as blood flow promoter [13], Docosahexaenoic 62 
acid (DHA), Eicosapentaenoic acid (EPA) and manganese. The supplements are 63 
administered as a gel pill. The manufacturer intake recommendation is one pill at night. 64 
 65 
Subjects were randomly divided in two groups. The daily group (DG) (n=18) were 66 
instructed to take the supplement from 22.00 to 23.00, before going to sleep, during 3 67 
consecutive days. IOP was measured at 10.00 and 11.00 am one day before, as 68 
baseline, and during the 3 days of experiment at the same time points. The acute 69 
group (AG) (n=49) was instructed to take the supplement at the morning only during 70 
one day. IOP was measured 1 hour and just before to take the supplement and one 71 
and two hours after. All measures in this group were taken one day before without any 72 
supplement (control) and the day of experiment by the same experienced examiners 73 
(C.R and J.B.).  74 
 75 
For IOP measurement, VX-130 platform (Luneau, Technologies, Chartres, France) was 76 
used. The VX130 is a multi-diagnostic platform that combines non-contact tonometer 77 
(air puff based) with Hartmann–Shack based autorefraction and Placido-disk and 78 
Scheimpflug based corneal-topography. Three measurements were taken on each 79 
subject and the average of the readings was recorded as the final IOP. The mean of 80 
measures at 10.00 and 11.00 was considered as basal value for each day. During the 81 
measurement, subjects were asked to keep the eye open and fixate to the light 82 
stimulus of the device.  83 
 84 
Data were analysed by statistical package SPSS version 22.0 for Windows (SPSS, 85 
Inc., Chicago, IL). The values presented are the means ± SD of the experiments 86 
performed. Parametric tests were used to compare the studied groups. Differences 87 
between baseline and after supplement intake in both groups were estimated by the 88 
Student - t test for related samples. One-way ANOVA for related samples were used to 89 
evaluate the trend of IOP in DG group. P <0.05 was considered statistically significant. 90 
 91 
The DG group showed a significant decreasing in IOP after supplement intake in all 92 
days of experiment compared with baseline, being 14.9 ± 3.4 mmHg for baseline and 93 
14.1 ± 2.7 mmHg, 13.6 ± 2.7 mmHg and 13.8 ± 2.9 mmHg after 24 hours, 48 hours and 94 
72 hours of experiment, respectively (p value<0.001; Student t-test for related 95 
samples). Moreover, the IOP trend during the complete experiment was to decrease, 96 
being statistically significant (p value<0.05; One-way ANOVA for related) Figure 1. 97 
 98 
Regarding AG group, IOP did not change during the control day, being 15.7 ± 2.4 99 
mmHg before to supplement intake and 15.6 ± 2.5 mmHg and 15.6 ± 2.6 mmHg after 100 
two and three hours, respectively (p value > 0.05; Student t-test for related samples). 101 
However, a reduction of 1 mmHg was found 2 hours after supplement intake, from 102 
15.7±2.5 mmHg to 14.7±2.5 mmHg, being statistically significant (p value < 0.05; 103 
Student t-test for related samples). After three hours, IOP followed being statistically 104 
inferior than baseline, with a mean value of 15.1±2.7 mmHg (p value < 0.05; Student t-105 
test for related samples). Figure 2. 106 
 107 
The nutritional supplement based on melatonin decreased IOP in normotensive 108 
subjects in both experiments performed. A single dose reduces IOP around 7% after 109 
two hours of its ingest and the consecutive intake for three days was able to reduce it 110 
around 9%.  111 
 112 
The effect of melatonin or analogues over IOP has been previously described in 113 
humans by oral intake. Samples et al. found that oral melatonin administration (500 114 
mg) reduced IOP in normal subject around 10% [8]. Pescosolido et al. found that 115 
agomelatine, a melatonin analogue, was able to reduce IOP around 30% after oral 116 
treatment in a group of primary open angle glaucoma patients. These patients were 117 
treated with 25 mg of agomelatine for psychiatric conditions [6]. Another study, 118 
published in 2009, has demonstrated IOP reduction when patients that underwent 119 
cataract surgery were treated with melatonin. These patients were treated with 10 mg 120 
of melatonin and IOP decreased significantly from 17.9 ± 0.9 to 14.2 ± 1.0 mmHg after 121 
premedication and to 13.8 ± 1.1 mmHg during surgery [7]. Both studies found an IOP 122 
reduction higher that the present trial probably due to the different concentration 123 
ingested and to the initial patient IOP.   124 
 125 
The main limitation of the study is that there is no placebo group, but results are 126 
compared to the measures of the same patient at the same time points in the previous 127 
day. It should also be considered that measures are performed with non-contact 128 
tonometer based on air-puff.  Some studies found that the non-contact tonometry gives 129 
higher results than Goldman tonometry, especially in adult subjects and hypertensive 130 
patients [14]. But, the repeatability of non-contact tonometry has been previously 131 
described in normotensive population [15]. It should be important to perform the same 132 
study with a placebo group and Goldman or Perkins tonometry in both normotensives 133 
and hypertensive patients to corroborate the outcomes of this study. 134 
 135 
The nutritional supplement evaluated is composed for other components with 136 
interesting features for glaucoma as it has been mentioned in methods section and, 137 
taking account the outcomes found in the current study, it would be interesting to 138 
design and develop some long-term studies to evaluate the supplement effect in retina 139 
protection. 140 
 141 
In conclusion, the nutritional supplement based on melatonin seems to decrease the 142 
IOP in normotensive subjects. These outcomes indicate that melatonin 143 
supplementation could be a coadjuvant treatment of glaucoma. Nevertheless, it is 144 
mandatory to confirm this role in glaucomatous patients compared with placebo group 145 
and with more studies about IOP changes after supplement intake. 146 
 147 
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FIGURES LEGENDS 209 
 210 
FIGURE 1. Effect on IOP during the three days of experiment in daily group (DG). 211 
n=18. It is represented the mean and standard error of the mean (SEM). * p 212 
value<0.05; after intake vs before intake (PRE) (Student t-test for related samples). 213 
 214 
 215 
FIGURE 2. Effect on IOP after two and three hours of a unique melatonin supplement 216 
intake in acute group (AG). n=49. It is represented the mean and standard error of the 217 
mean (SEM). * p value<0.05; after intake vs before intake (PRE) (Student t-test for 218 
related samples). 219 
 220 
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